Drugs / Curodont D'Senz
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 41 trial | ||||||
| Phase 4 | NCT05122312 | Apr → Nov 2020 | dentin sensitivity | Al-Azhar University | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT06829277 | Nov 2024 → Jan 2025 | dentin sensitivity | MTI University | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Curodont D'Senz | “Self-assembling peptide matrix (P11-4) supplied commercially as Curodont D'Senz (CS) gel (Credentis AG, Windisch, Switzerland) is based on the nanofiber technology that...” NCT06829277 ↗2“This study was conducted to evaluate and compare the efficacy of Olinanoseal and Curodont D'Senz in treatment of dentin hypersensitivity.” NCT05122312 ↗ |
| Modality | Peptide | “This agent contains p 11-4 peptide in addition to fluoride” NCT05122312 ↗ |
| Route | Topical | “desensitizing agent to remain above tooth surface for one minute before laser irradiation” NCT06829277 ↗ |